Immunotherapy in EGFR-mutant non-small cell lung cancer.

Abstract excerpt

Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR).For driver mutations, the use of EGFR tyrosine kinase inhibitors (TKIs) is the standard treatment, but acquired resistance is inevitable. There is currently no standard treatment for first-line TKI-resistant NSCLC patients. In recent years, although immune checkpoint inhibitors (ICIs) have transformed the treatment...

Topics

• Humans
• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors
• Lung Neoplasms
• Mutation
• Immunotherapy
• Immune Checkpoint Inhibitors